.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,700,662

« Back to Dashboard

Details for Patent: 5,700,662

Title: Process for preparing insulin analogs
Abstract:Recombinant processes for preparing insulin analogs modified at position 29 of the B-chain and, optionally, at other positions are claimed. The analogs produced using the claimed processes have modified physico-chemical properties and are useful in treating hyperglycemia.
Inventor(s): Chance; Ronald E. (Westfield, IN), DiMarchi; Richard D. (Carmel, IN), Frank; Bruce H. (Indianapolis, IN), Shields; James E. (Noblesville, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Filing Date:Jun 06, 1995
Application Number:08/465,847
Claims:1. A process for preparing a therapeutically active insulin analog of the formula; ##STR9## or a pharmaceutically acceptable salt thereof, wherein A.sub.21 is Asn, or Ala;

B.sub.1 is Phe, or is absent;

B.sub.2 is Val, or is absent;

B.sub.10 is His, or Asp;

B.sub.28 is any amino acid;

B.sub.29 is L-Pro, D-Pro, L-hydroxyproline, D-hydroxyproline; and,

B.sub.30 is Thr, Ala, or is absent; said method comprising:

i) transforming a host cell with DNA that encodes a proinsulin-like precursor molecule having the A and B chains of Formula (I);

ii) culturing the recombinant host cell under conditions suitable for expressing the DNA used to transform the host cell and isolating the proinsulin-like precursor molecule encoded by the DNA in step i);

iii) enzymatically cleaving the proinsulin-like precursor molecule to remove the connecting peptide; and,

iv) recovering the insulin analog.

2. The process of claim 1 wherein B.sub.28 is Asp, Val, Leu, Ile, Pro, Arg, His, Lys, Phe, Ala, Gly, norisoleucine, citrulline, or ornithine.

3. The process of claim 1 wherein A.sub.21 is Ala, B.sub.1 is Phe, B.sub.2 is Val, B.sub.10 is His, B.sub.28 is Lys, B.sub.29 is Pro, and B.sub.30 is Thr.

4. The process of claim 1 wherein A.sub.21 is Asn, B.sub.1 is absent, B.sub.2 is Val, B.sub.10 is His, B.sub.28 is Lys, B.sub.29 is Pro, and B.sub.30 is Thr.

5. The process of claim 1 wherein A.sub.21 is Asn, B.sub.1 is absent, B.sub.2 is Val, B.sub.10 is Asp, B.sub.28 is Lys, B.sub.29 is Pro, and B.sub.30 is Thr.

6. The process of claim 1 wherein A.sub.21 is Asn, B.sub.1 is absent, B.sub.2 is absent, B.sub.10 is His, B.sub.28 is Lys, B.sub.29 is Pro, and B.sub.30 is Thr.

7. The process of claim 1 wherein A.sub.21 is Asn, B.sub.1 is absent, B.sub.2 is absent, B.sub.10 is Asp, B.sub.28 is Lys, B.sub.29 is Pro, and B.sub.30 is Thr.

8. The process of claim 1 wherein A.sub.21 is Asn, B.sub.1 is Phe, B.sub.2 is Val, B.sub.10 is His, B.sub.28 is Lys, B.sub.29 is Pro, and B.sub.30 is absent.

9. The process of claim 1 wherein A.sub.21 is Asn, B.sub.1 is Phe, B.sub.2 is Val, B.sub.10 is His, B.sub.28 is Lys, B.sub.29 is Pro, and B.sub.30 is Ala.

10. A process for preparing a therapeutically active insulin analog of the formula; ##STR10## or a pharmaceutically acceptable salt thereof; said method comprising: i) transforming a host cell with DNA that encodes a proinsulin-like precursor molecule having the A and B chains of Formula (II);

ii) culturing the recombinant host cell under conditions suitable for expressing the DNA used to transform the host cell and isolating the proinsulin-like precursor molecule encoded by the DNA in step i);

iii) enzymatically cleaving the proinsulin-like precursor molecule to remove the connecting peptide; and,

iv) recovering the insulin analog.

11. A process for preparing a therapeutically active insulin analog of the formula; ##STR11## or a pharmaceutically acceptable salt thereof, wherein A.sub.21 is Asn, or Ala;

B.sub.1 is Phe, or is absent;

B.sub.2 is Val, or is absent;

B.sub.10 is His, or Asp;

B.sub.28 is any amino acid;

B.sub.29 is L-Pro, D-Pro, L-hydroxyproline, D-hydroxyproline; and,

B.sub.30 is Thr, Ala, or is absent; said method comprising:

i) transforming a host cell with DNA that individually encodes the A and B chains of Formula (I);

ii) culturing the recombinant host cell under conditions suitable for expressing the DNA used to transform the host cell and isolating the A and B chains of Formula (I) encoded by the DNA in step i);

iii) combining the individual A and B chains to produce a insulin analog of Formula (I); and,

iv) recovering the insulin analog.

12. The process of claim 11 wherein B.sub.28 is Asp, Val, Leu, Ile, Pro, Arg, His, Lys, Phe, Ala, Gly, norisoleucine, citrulline, or ornithine.

13. The process of claim 11 wherein A.sub.21 is Ala, B.sub.1 is Phe, B.sub.2 is Val, B.sub.10 is His, B.sub.28 is Lys, B.sub.29 is Pro, and B.sub.30 is Thr.

14. The process of claim 11 wherein A.sub.21 is Ash, B.sub.1 is absent, B.sub.2 is Val, B.sub.10 is His, B.sub.28 is Lys, B.sub.29 is Pro, and B.sub.30 is Thr.

15. The process of claim 11 wherein A.sub.21 is Ash, B.sub.1 is absent, B.sub.2 is Val, B.sub.10 is Asp, B.sub.28 is Lys, B.sub.29 is Pro, and B.sub.30 is Thr.

16. The process of claim 11 wherein A.sub.21 is Asn, B.sub.1 is absent, B.sub.2 is absent, B.sub.10 is His, B.sub.28 is Lys, B.sub.29 is Pro, and B.sub.30 is Thr.

17. The process of claim 11 wherein A.sub.21 is Ash, B.sub.1 is absent, B.sub.2 is absent, B.sub.10 is Asp, B.sub.28 is Lys, B.sub.29 is Pro, and C.sub.30 is Thr.

18. The process of claim 11 wherein A.sub.21 is Asn, B.sub.1 is Phe, B.sub.2 is Val, B.sub.10 is His, B.sub.28 is Lys, B.sub.29 is Pro, and B.sub.30 is absent.

19. The process of claim 11 wherein A.sub.21 is Asn, B.sub.1 is Phe, B.sub.2 is Val, B.sub.10 is His, B.sub.28 is Lys, B.sub.29 is Pro, and B.sub.30 is Ala.

20. A process for preparing a therapeutically active insulin analog of the formula; ##STR12## or a pharmaceutically acceptable salt thereof; said method comprising: i) transforming a host cell with DNA that encodes a proinsulin-like precursor molecule having the A and B chains of Formula (I);

ii) culturing the recombinant host cell under conditions suitable for expressing the DNA used to transform the host cell and isolating the proinsulin-like precursor molecule encoded by the DNA in step i);

iii) enzymatically cleaving the proinsulin-like precursor molecule to remove the connecting peptide; and,

iv) recovering the insulin analog.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc